Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

56.26 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

January 06, 2026

Novo Nordisk's new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the forefront of the weight loss market.

Via The Motley Fool

Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial? ↗

January 06, 2026

Novo Nordisk has some good GLP-1 news, but is the company's failed Alzheimer's trial a long-term problem?

Via The Motley Fool

Topics Intellectual Property

The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026

January 06, 2026

As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a...

Via MarketMinute

Topics Economy

Novo Nordisk Offers Oral Wegovy Pill At $149 A Month Following FDA’s Approval In December: Retail Tells Shorts ‘It’s Time To Give Up’ ↗

January 05, 2026

Via Stocktwits

The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026

January 06, 2026

As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence...

Via MarketMinute

Topics Artificial Intelligence Economy Government

The Great 2026 Pivot: Tech and Healthcare Surge as Broader Market Rally Hits a Wall

January 06, 2026

As the first week of 2026 comes to a close, the financial markets are undergoing a significant structural shift. The broad-based "rising tide" that lifted almost all sectors throughout 2025 has begun...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value? ↗

January 06, 2026

Eli Lilly offers investors safety and growth.

Via The Motley Fool

Eli Lilly Heads Toward A Defining 2026 — Can It Stay Ahead Of Novo Nordisk In The GLP-1 Showdown? ↗

January 06, 2026

Several clinical readouts and regulatory decisions are scheduled for Eli Lilly in 2026.

Via Stocktwits

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗

January 05, 2026

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Via Stocktwits

Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms ↗

January 05, 2026

Novo’s pricing applies to lower-dose oral Wegovy, with higher doses set at higher monthly prices.

Via Stocktwits

Is It Time to Dump Your Shares of Eli Lilly? ↗

January 05, 2026

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Via The Motley Fool

2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 ↗

January 03, 2026

The pharmaceutical leader looks poised to stop the bleeding.

Via The Motley Fool

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

Via MarketMinute

Topics Economy Intellectual Property World Trade

The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026

January 02, 2026

As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and...

Via MarketMinute

Topics Economy Intellectual Property

Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30

January 01, 2026

As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical...

Via MarketMinute

Topics Intellectual Property

The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature

January 01, 2026

As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has...

Via PredictStreet

Topics Economy Lawsuit World Trade

The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings

December 31, 2025

As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026 ↗

December 31, 2025

Via MarketBeat

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Why Novo Nordisk Stock Dropped on Monday ↗

December 30, 2025

The cost of Wegovy is about to decrease significantly in a populous overseas market.

Via The Motley Fool

Topics Intellectual Property

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three...

Via MarketMinute

Topics ETFs Economy World Trade

The 2026 Horizon: Wall Street Bets on the 'Application Era' and the Nuclear Renaissance

December 29, 2025

As the final trading days of 2025 come to a close, Wall Street is pivoting its focus from the hardware-driven "AI Gold Rush" toward a 2026 outlook defined by practical utility, autonomous software, and...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Topics ETFs Intellectual Property

The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance

December 29, 2025

As of late 2025, the global pharmaceutical landscape has undergone a tectonic shift, and at its center stands Eli Lilly and Company (NYSE: LLY). Once regarded as a steady, dividend-paying stalwart of...

Via PredictStreet

Topics Earnings Economy Intellectual Property

Market Breather: Benchmarks Pause Record-Breaking Year as Volatility Signals Year-End Reset

December 29, 2025

As the final trading days of 2025 approach, the relentless momentum that propelled major U.S. indices to historic heights has entered a period of measured consolidation. After a year defined by the...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

This Beaten-Down Stock Just Jumped By 8%. Time to Buy? ↗

December 29, 2025

Is this the start of a sustained run for the Danish drugmaker?

Via The Motley Fool

Novo Nordisk Slashes Weight Loss Drug Price By Up To 50% In China: Report ↗

December 29, 2025

Prices of Wegovy’s two highest doses were reduced to 987.48 yuan ($141) and 1,284.36 yuan, according to a Bloomberg article on Monday, citing Yicai.

Via Stocktwits

Topics Intellectual Property

The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA. ↗

December 29, 2025

Other drugmakers seem to be too far behind to disrupt this duopoly, at least for now.

Via The Motley Fool

3 Drug Stocks to Buy at a Discount ↗

December 27, 2025

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Via The Motley Fool

Topics Intellectual Property

Should You Invest in Ozempic Maker Novo Nordisk in 2026? ↗

December 26, 2025

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.